Merli M, Caschera M, Piat C, Pinto G, Diofebi M, Riggio O
IInd Cattedra di Gastroenterologia Università, La Sapienza di Roma, Italy.
J Clin Gastroenterol. 1992 Sep;15(2):125-7. doi: 10.1097/00004836-199209000-00009.
Mild to moderate fat malabsorption is frequently present in patients with liver cirrhosis. We investigated the influence of lactulose or lactitol treatment on fecal fat excretion in 18 patients with liver cirrhosis. All patients were Child Pugh class A or B and had not taken any therapy that could have affected intestinal absorption in the previous months. The dose of lactulose or lactitol was individually adjusted to maintain two semiliquid bowel movements per day. Steatorrhea was determined before and after a minimum of 7 days, when the cathartic effect was stabilized. Treatment with nonabsorbable disaccharides induced mild to moderate steatorrhea in 50% of patients. No differences were observed between the effects of lactulose and lactitol, but fecal fat excretion exceeded 10 g/day in two patients taking lactulose. These findings indicate that treatment with nonabsorbable disaccharides may increase fecal fat excretion in patients with liver cirrhosis. This factor should be taken into consideration when a cirrhotic patient has to take these drugs for a long time.
肝硬化患者常存在轻至中度脂肪吸收不良。我们研究了乳果糖或乳糖醇治疗对18例肝硬化患者粪便脂肪排泄的影响。所有患者均为Child Pugh A级或B级,且在之前数月未接受任何可能影响肠道吸收的治疗。乳果糖或乳糖醇的剂量根据个体情况调整,以维持每天两次半流质大便。在至少7天泻药作用稳定后,测定治疗前后的脂肪泻情况。不可吸收双糖治疗使50%的患者出现轻至中度脂肪泻。乳果糖和乳糖醇的效果之间未观察到差异,但两名服用乳果糖的患者粪便脂肪排泄超过10克/天。这些发现表明,不可吸收双糖治疗可能会增加肝硬化患者的粪便脂肪排泄。当肝硬化患者必须长期服用这些药物时,应考虑这一因素。